+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 0 - 18Years
All Genders
ID04794296

Treatment Recommendations for Children With Acute Lymphoblastic Leukemia ALL in the GFAOP Study

Led by French Africa Pediatric Oncology Group · Updated on 2026-03-02

500

Participants Needed

3

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating new treatment recommendations for children with Acute Lymphoblastic Leukemia ALL through the GFAOP group. This observational study aims to improve outcomes by applying precise protocols and logistical support in developing countries. The study includes both standard and high-risk ALL forms, focusing on achieving high remission rates and long-term survival. The treatment approach proposes anthracycline induction for high-risk cases, including children under 1 year or over 10 years, and uses Endoxan and high-dose Methotrexate in consolidation phases. The study also follows previously established protocols for standard risk patients, aiming to refine and confirm effective treatment strategies for children with ALL. Participants will be monitored for treatment feasibility, adherence, remission rates after induction, and survival without relapse over five years. Assessments include checking correct application of therapy within five weeks and complete remission around day 34 to 42 post-induction. The study expects to evaluate outcomes initially after two years and fully by five years, ensuring comprehensive follow-up and data collection throughout the study period.

CONDITIONS

Brief Title

Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP

Research Team

N

Ndella Ms DIOUF, MD

B

BRENDA Ms MALLON, MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here